Abstract
Objectives:To investigate the clinical efficacy of budesonide suspension through bronchofiberscopic lavage in the treatment of refractory mycoplasma pneumoniae pneumonia.(RMPP)Methods:A total of 108 children with refractory mycoplasma pneumoniae pneumonia from June 2018 to October 2020 were randomly divided into two groups: the study group and the control group, with 54 cases in each group. Children in the control group were treated with anti-infective, antitussive, antipyretic routine symptomatic treatment and nebulization of budesonide suspension, while children in the study group were treated with bronchofiberscopic lavage with Budesonide suspension along with standard treatment as in control group. The clinical efficacy, changes in blood gas analysis indexes, levels of inflammatory mediators, time for improvement of clinical symptoms and the incidence of adverse reactions were compared between the two groups.Results:The efficacy of treatment in the study group was 85.19%, which was higher than 66.67% in the control group (P<0.05). The antipyretic time, antitussive time, lung rales disappearance time and length of hospital stay in the study group were shorter than those in the control group (P<0.05). Moreover, the levels of arterial oxygen partial pressure (PaO2) in the study group were higher than those in the control group, while the levels of partial pressure of carbon dioxide (PaCO2) and arterial oxygen saturation (SaO2) in the study group were lower than those in the control group (P<0.05). The levels of inflammatory mediators interleukin-6 (IL-6), interleukin-4 (IL-4), and interferon-γ (IFN-γ) in the study group were lower than those in the control group (P<0.05), and no significant difference was found in the comparison of the incidence of adverse reactions between the two groups (P>0.05).Conclusions:Budesonide suspension combined with bronchofiberscopic lavage with Budesonide suspension is a safe treatment regimen that can significantly improve the clinical outcome in children with RMPP. With such a combined treatment regimen, the clinical symptoms of children can be ameliorated, the ventilation function can be enhanced, and the level of inflammatory mediators will be reduced.
Highlights
Mycoplasma pneumoniae pneumonia, as an interstitial pneumonia caused by mycoplasma pneumoniae infection, is one of the most common respiratory infections in clinical practice, with an increasing incidence year by year.[1-3]
The clinical efficacy of bronchofiberscopic lavage combined with budesonide suspension in the treatment of refractory mycoplasma pneumoniae pneumonia (RMPP) was investigated, and adverse reactions were observed
A total of 108 children with RMPP from June 2018 to October 2020 were randomly divided into two groups: the study group and the control group, with 54 cases in each group
Summary
Mycoplasma pneumoniae pneumonia, as an interstitial pneumonia caused by mycoplasma pneumoniae infection, is one of the most common respiratory infections in clinical practice, with an increasing incidence year by year.[1-3]. Macrolide antibiotics are currently the preferred treatment drugs for refractory mycoplasma pneumoniae. Pak J Med Sci March - April 2022 (Part-II) Vol 38 No 4 www.pjms.org.pk 922 pneumonia (RMPP). With the increase of mycoplasma resistance to macrolide antibiotics, conventional macrolide antibiotics alone have poor efficacy in the treatment of RMPP.[4,5]. With the maturity of bronchoscopy technology, the therapeutic value of alveolar lavage on infected sites has been widely recognized.[7]. Local administration of budesonide after bronchoscopic alveolar lavage may achieve better efficacy. The clinical efficacy of bronchofiberscopic lavage combined with budesonide suspension in the treatment of RMPP was investigated, and adverse reactions were observed
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
